- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03587610
Evaluation of a Tdap-IPV (Tetanus, Diphteria, Pertussis and Inactivated Polio) Vaccination Remedial Strategy on Vaccination Coverage in Patients 65 Years of Age or Older (HOSPIVAC)
Evaluation of a Tdap-IPV Vaccination Remedial Strategy on Vaccination Coverage in Patients 65 Years of Age or Older in the French County of Sarthe
In France, vaccination coverage is insufficient (in 2002, 71.2% coverage for tetanus, 41.9% for poliomyelitis and 33.7% for diphteria). These numbers decrease significantly with age: coverage for people aged over 65 was 60.5%, 13.3% and 10.5% for tetanus, poliomyelitis and diphteria coverage respectively.
The primary objective of this study is to evaluate the impact of a hospital based vaccination remedial strategy for Tdap-IPV (tetanus, diphteria, pertussis and polio vaccine) in patients 65 years of age or older.
Secondary objectives are to measure the vaccination coverage of patients aged 65 years or older hospitalised in a medical ward in our hospital, to evaluate their knowledge of their vaccination coverage, and to evaluate the socio-demographic factors associated with vaccination coverage.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Le Mans, France, 72 000
- Centre Hospitalier Le Mans
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged 65 years or older
- Patients capable of understanding and giving informed consent to participate in the study
- Valid social security coverage
Exclusion Criteria:
- Patients under judicial safeguard measures
- Refusal to participate in the study
- Vaccination contra-indication
- Patient already included in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Intervention arm
|
|
|
No Intervention: Standard care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in immunization rate after a hospital centered remedial strategy for Tdap-IPV vaccination in patients 65 years or older
Time Frame: two months
|
Difference in the increase in vaccination coverage between the two arms, measured as a percentage
|
two months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Immunisation rate among patients 65 years of age or older in the Sarthe department of France
Time Frame: two months
|
Pre-intervention vaccination coverage rate in both arms, measured as a percentage
|
two months
|
|
Immunisation rate according to sex among patients 65 years or older
Time Frame: two months
|
Sex of patients included in the study
|
two months
|
|
Immunisation rate according to primary care coverage among patients 65 years of age or older
Time Frame: two months
|
Primary care coverage is defined as having a regular primary care physician registered as such with French social security.
|
two months
|
|
Immunisation rate according to socio professional category
Time Frame: two months
|
Socio professional category defined according to the French national institute for statistics and economic studies (INSEE)
|
two months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sophie Blanchi, M.D., Centre Hospitalier du Mans
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- CHM-2017-S6/06
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.